Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius SE & Co. KGaA    FRE   DE0005785604

FRESENIUS SE & CO. KGAA

(FRE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius : Vamed completes main university hospital building in Kiel

share with twitter share with LinkedIn share with facebook
share via e-mail
1
08/20/2019 | 12:17pm EDT

After four years of construction Fresenius Vamed has completed the new main building at University Hospital Schleswig-Holstein (UKSH) in Kiel. The completion marks the first milestone in the modernization of Germany's second-largest university hospital, with the main building of the Lübeck location scheduled to open in November. The project includes new construction and the comprehensive renovation of the two university hospital locations, some 80 kilometers (50 miles) apart in Schleswig-Holstein state, and their technical management through 2044. With a total volume of €1.7 billion, the UKSH's modernization is currently the biggest public-private partnership project in Europe's healthcare sector.

Disclaimer

Fresenius SE & Co. KGaA published this content on 20 August 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 August 2019 16:16:09 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
1
Latest news on FRESENIUS SE & CO. KGAA
09/16FRESENIUS : 2020 DRG inflator for German hospitals set at 3.66%
PU
09/15Fresenius drops possible sale of blood transfusion unit - spokesman
RE
09/13FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
09/11FRESENIUS : Helios launches digital portal for patients
PU
09/09FRESENIUS : Medical Care's publishes annual medical report
PU
09/06FRESENIUS : Medical Care builds new laboratory in Mississippi
PU
09/05Fresenius Medical Care to Invest in Its Stem-Cell Subsidiary Unicyte
DJ
09/05FRESENIUS : Medical Care invests EUR 60 million in Unicyte
PU
09/03Fresenius Helios Acquires Two Hospitals in Colombia
DJ
08/30FRESENIUS : Kabi launches IV Drug in the U.S.
PU
More news
Financials (EUR)
Sales 2019 35 397 M
EBIT 2019 4 683 M
Net income 2019 1 838 M
Debt 2019 20 938 M
Yield 2019 1,81%
P/E ratio 2019 13,4x
P/E ratio 2020 12,2x
EV / Sales2019 1,29x
EV / Sales2020 1,14x
Capitalization 24 705 M
Chart FRESENIUS SE & CO. KGAA
Duration : Period :
Fresenius SE & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS SE & CO. KGAA
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 56,25  €
Last Close Price 44,07  €
Spread / Highest target 69,7%
Spread / Average Target 27,6%
Spread / Lowest Target -26,3%
EPS Revisions
Managers
NameTitle
Stephan Sturm President & Chief Executive Officer
Gerd Krick Chairman-Supervisory Board
Rachel Clare Empey Chief Financial Officer
Niko Stumpfögger Deputy Chairman-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Sector and Competitors